167552-44-5

Upstream product

• 504-24-5 4-aminopyridine 
• 79463-77-7 N-cyanodiphenylcarbonimidate 

Downstream Products

• 1620289-89-5 1-((5-(([1,1'-biphenyl]-2-yloxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)-2-cyano-3-(pyridin-4-yl)guanidine 
• 1325728-75-3 N-cyano-N'-(6-(2-difluoromethoxy-5-chlorophenoxy)hexyl)-N-(4-pyridyl) guanidine 

Relevant academic research and scientific papers

Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists

Here we report adamantyl cyanoguanidine compounds based on hybrids of the adamantyl amide scaffold reported by AstraZeneca and cyanoguanidine scaffold reported by Abbott Laboratories. Compound 27 displayed five-fold greater inhibitory potency than the lea

4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS

The present invention provides substituted 4,5-dihydroisoxazole derivatives of formula (I), which may be therapeutically useful, more particularly NAMPT inhibitors and in which R1 R2, Y, X, "Het" and "p" have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPT) in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted 4,5-dihydroisoxazole derivatives of formula (I) or a pharmaceutically acceptable salts or stereoisomers or N-oxide thereof.

PYRIDYL CYANOGUANIDINE DERIVATIVES

Compounds of formula (I) or pharmaceutically acceptable salts thereof, and use for treating cancer thereof are disclosed, wherein, the definitions of X, Y, R1, R2 and n are described in description.